Wednesday, April 1, 2020

Novartis scraps sale of assets to Aurobindo Pharma after failing to get FTC nod

Novartis scraps sale of assets to Aurobindo Pharma after failing to get FTC nod Novartis said the decision to terminate the sale of Sandoz US#39;s generic oral solids and dermatology businesses was taken after the companies did not get approval from the U.S. Federal Trade Commission within anticipated timelines.

from Moneycontrol Business News https://ift.tt/2X3yjLJ
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Largecap valuations near fair value, time to start deploying: Jyotivardhan Jaipuria

​So, banks are cheap. And second is, at these valuations, a lot of bad news is priced in. So, as we see growth coming back, as we see things...